Global PARG Inhibitor Market 2026 by Company, Regions, Type and Application, Forecast to 2032

According to our (Global Info Research) latest study, the global PARG Inhibitor market size was valued at US$ 0.31 million in 2025 and is forecast to a readjusted size of US$ 1.61 million by 2032 with a CAGR of 20.5% during review period.
A PARG inhibitor blocks poly(ADP-ribose) glycohydrolase, which removes poly(ADP-ribose) chains during cellular DNA-damage responses. Preventing this turnover can disrupt replication-fork recovery and increase replication stress in susceptible tumour cells. Unlike PARP inhibition, it acts on polymer degradation rather than synthesis. Development requires selective engagement, sufficient intracellular exposure, pharmacodynamic evidence and a therapeutic window between tumour and normal proliferating tissue. Clinical value depends on tolerable, durable activity in defined populations, not an assumption that all PARP-resistant cancers respond.
Key Findings
PARG inhibition targets polymer removal within DNA damage response pathways
Clinical development separates monotherapy testing from emerging combination strategies
Biomarker selection must be validated rather than borrowed from PARP
Market Trends
PARG development is moving from target rationale into human dose selection and combination testing. IDE161 is being evaluated with a TOP1-payload ADC, and ETX-19477 has a first-in-human programme. DAT-2645, SYN608 and QLS1403 provide distinct Chinese development routes. Exposure, pharmacodynamics and reproducible cohort activity increasingly determine progress, with different evidence levels requiring separate interpretation.
Market Dynamics
Drivers
Impaired fork protection or high replication stress creates a rationale for disrupting PARG-mediated turnover. Unmet needs after existing DNA-repair therapies support clinical investment. Current direct demand is for controlled evaluation and translational assays rather than routine hospital drug purchasing.
Restraints
PARG also participates in normal DNA responses, so an adequate therapeutic window is not guaranteed. Early cohorts provide incomplete information on durability and uncommon toxicity. Without an approved label and pricing evidence, revenue projections remain less grounded than development milestones.
Opportunities
TOP1-payload combinations can test whether impaired repair of payload-induced lesions adds antitumour activity. Overlapping toxicity requires an independently evaluated schedule. Molecularly selected ovarian and breast cancer studies offer another route, but PARP resistance alone is not a validated universal selection rule.
Challenges
Preclinical biomarker signals may not predict benefit across heterogeneous human tumours. Prospective sampling, consistent assays and follow-up are needed to separate activity from cohort-selection effects. Funding continuity and feasible comparative trials determine whether dose-escalation findings can reach registration.
Industry Chain Analysis
Enzyme assays, chemistry and replication-stress models initiate PARG programmes. Synthesis and formulation teams produce clinical material; sponsors, hospitals and laboratories coordinate escalation, exposure analysis and pharmacodynamic sampling. Value currently resides in intellectual property and human proof of concept. Licensing and research contracts are not finished-drug sales. A commercial chain additionally requires registration, reproducible GMP scale-up, distribution and a payable treatment pathway.
Segment Insights
IDE161 combines dose optimization with clinical combination work, making schedule and pharmacodynamic compatibility central. ETX-19477 has first-in-human development and company updates on initial patient data; these do not establish comparative superiority. DAT-2645 provides a Chinese clinical route. SYN608 has documented clinical authorization, but patient outcomes must not be inferred from permission to start a trial. QLS1403 has company-disclosed preclinical evidence and is classified at that verified level here. The residual molecule category accommodates later assets without turning undisclosed compounds or reagent catalogues into established therapeutic competitors.
Downstream Market Opportunities
Ovarian studies must record platinum resistance, molecular criteria and prior therapy. Breast cohorts need separate interpretation by hormone receptors, BRCA status and treatment history. Endometrial combinations must show PARG contribution beyond the partner. Small-cell lung cancer TOP1-payload combinations address a different context and cannot inherit ovarian response assumptions. Other tumour cohorts remain exploratory until activity and a registration strategy are established.
Regional Insights
The United States hosts important IDE161 and ETX-19477 programmes. China contributes original development through Danatlas, SynRx and Qilu, with Chinese trials and US authorization appearing in different projects. These describe research geography, not drug-sales shares. Tissue access, trial capacity and previous treatment affect cross-region data transferability. European and Japanese participation may develop later, but current evidence does not justify assigning commercial totals to those regions.
Competitive Landscape Analysis
Representative companies include IDEAYA Biosciences, 858 Therapeutics, Danatlas Pharmaceuticals, SynRx Therapeutics and Qilu Pharmaceutical. IDEAYA advances IDE161 combinations; 858 develops ETX-19477 in humans; Danatlas progresses DAT-2645 clinically; SynRx has disclosed SYN608 authorization; Qilu has presented QLS1403 preclinical work. Competition centres on validated selection, exposure and safety and a credible registration route. Different stages and cohorts cannot produce a direct efficacy ranking or an approved manufacturing position.
Report Scope
This report is a detailed and comprehensive analysis for global PARG Inhibitor market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global PARG Inhibitor market size and forecasts, in consumption value ($ Million), 2021-2032
Global PARG Inhibitor market size and forecasts by region and country, in consumption value ($ Million), 2021-2032
Global PARG Inhibitor market size and forecasts, by Type and by Application, in consumption value ($ Million), 2021-2032
Global PARG Inhibitor market shares of main players, in revenue ($ Million), 2021-2026
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for PARG Inhibitor
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global PARG Inhibitor market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include IDEAYA Biosciences, 858 Therapeutics, Danatlas Pharmaceuticals, SynRx Therapeutics, Qilu Pharmaceutical, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
PARG Inhibitor market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for Consumption Value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segmentation
Market segment by Type
IDE161
ETX-19477
DAT-2645
SYN608
QLS1403
Others
Market segment by Biomarker Strategy
BRCA1/2 Mutation-selected
Others
Market segment by Application
Ovarian Cancer
Breast Cancer
Endometrial Cancer
Small-cell Lung Cancer
Others
Market segment by players, this report covers
IDEAYA Biosciences
858 Therapeutics
Danatlas Pharmaceuticals
SynRx Therapeutics
Qilu Pharmaceutical
Market segment by regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia and Rest of Asia-Pacific)
South America (Brazil, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
Chapter Outline
Chapter 1, to describe PARG Inhibitor product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of PARG Inhibitor, with revenue, gross margin, and global market share of PARG Inhibitor from 2021 to 2026.
Chapter 3, the PARG Inhibitor competitive situation, revenue, and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and by Application, with consumption value and growth rate by Type, by Application, from 2021 to 2032.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2021 to 2026.and PARG Inhibitor market forecast, by regions, by Type and by Application, with consumption value, from 2027 to 2032.
Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis.
Chapter 12, the key raw materials and key suppliers, and industry chain of PARG Inhibitor.
Chapter 13, to describe PARG Inhibitor research findings and conclusion.